In The News

    • APR 19 2016

    Computer to clinic: Tool developed at Weill predicts drug success

    Weill Cornell Medical College highlights the collaboration between Oncoceutics and the lab of Dr. Olivier Elemento, which used a computer algorithm developed in Dr. Elemento’s lab to predict the interaction between ONC201 and Dopamine Receptor 2, which was later validated by Oncoceutics. Computer to clinic: Tool developed at Weill predicts drug success

    • APR 12 2016

    PharmaVoice Highlights Oncoceutics in Article on Innovative Funding for Biotechs

    Oncoceutics’ financing strategy, utilizing significant non-dilutive capital from grants and strategic partnerships with leading cancer institutes, was highlighted in an article published by PharmaVoice. The article, titled “Innovation Financing, Venture Capital and More” can be read in full here.

    • MAR 24 2016

    Oncoceutics Highlighted by German American Chamber of Commerce of Philadelphia

    The following article appeared in the March 2016 Member Newsletter of the German American Chamber of Commerce, Philadelphia Oncoceutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of highly differentiated treatments for difficult cancers. The company was founded in 2009 by GACC member Wolfgang Oster, Lee Schalop, and scientific founder Wafik

    • MAR 04 2016

    Dr. Joshua Allen Interviewed for the Innovator’s Corner by PharmaVoice

    Read the full article at PharmaVoice Dr. Joshua Allen, VP for Research and Development at Oncoceutics, talks about his company’s approach to target cancer. Targeted therapies are the focus of many cancer drug development programs. They are a cornerstone of precision medicine, which uses information about a person’s genes and proteins to prevent, diagnose, and